Takeda: Dengue trials

The registry lists 21 Dengue studies with Takeda as lead sponsor. 2 are open to participants now and 15 have results posted.

Phase 1 2Phase 2 7Phase 3 11No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for DengueRecruitingNCT06843226
• A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and ToddlersRecruitingNCT06665035Phase 3
• Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 YearsCompletedNCT04313244Phase 3Results posted
• Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster DoseCompletedNCT03999996Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy AdultsCompletedNCT03771963Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune AdultsCompletedNCT03746015Phase 2Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus VaccineCompletedNCT03525119Phase 3Results posted
• Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for DengueCompletedNCT03423173Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in AdultsCompletedNCT03342898Phase 3Results posted
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)CompletedNCT03341637Phase 3Results posted
• Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy ChildrenCompletedNCT02948829Phase 2Results posted
• Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in SingaporeCompletedNCT02425098Phase 2Results posted
• Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy ParticipantsCompletedNCT02302066Phase 2Results posted
• Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)CompletedNCT02193087Phase 2Results posted
• Impact of SC vs IM Administration of DENVax (TDV) on Safety and ImmunogenicityCompletedNCT01728792Phase 1Results posted
• A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult VolunteersCompletedNCT01542632Phase 1Results posted
• Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 YearsCompletedNCT01511250Phase 2Results posted
• A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsActive, not recruitingNCT07047521Phase 3
• A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in JapanCompletedNCT06741683Phase 2/3
• A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)Active, not recruitingNCT06579755Phase 3
• A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in MalaysiaActive, not recruitingNCT06388785